In this week's Pharma Pulse, DHL breaks ground on a new cold chain hub at Singapore's Changi Airport, a new report finds pharma's commercial model in the middle of a fundamental reset, and the FDA grants accelerated approval to sevabertinib.
Commentary|Podcasts|March 31, 2025
Embarking on the CAR-T Journey
Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these treatments.
Advertisement
In this exclusive PC Podcast interview, Renier Brentjens, MD, PhD, deputy director and chair of medicine at the Roswell Park Comprehensive Cancer Center, discusses:
- How he has seen the field evolve since its inception, and what excites him most about its future
- How the Roswell Park expansion helps improve patient access to CAR T-cell therapy
- The key safety concerns associated with CAR T-cell therapy, along with how Roswell Park aims to mitigate potential risks
- How Roswell Park is working to make CAR T-cell therapy more widely available
- The steps needed to be taken at the regulatory and healthcare policy levels in order to support the broader adoption of CAR T-cell therapy
The latest episode of The Pharmaceutical Commerce Podcast is available directly on
Advertisement
Related to this article
Patient support data that is trusted, connected and delivered into field workflows can move access teams from reporting to faster patient intervention.
In this week's Pharma Pulse, the EU Council adopts the "pharma package," Commerce details 0% tariffs for certain drugs and Sharp expands autoinjector assembly capacity.
HDA's Kala Shankle says a federal licensure baseline could bring real efficiency gains for wholesale distributors and 3PLs, but only if state requirements align and every stakeholder moves on the same timeline.
With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.
As patient expectations continue to evolve, brick-and-mortar pharmacy’s path forward lies in combining trusted, face-to-face care with the efficiency and convenience patients increasingly value.
In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and HRSA's 340B rebate pilot deadline arrives.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How the GLP-1 Boom Stress-Tests the Pharma Cold Chain
2
Doceree CEO: AI Should Extend the Field Force, Not Replace It
3
Pharma Pulse: EU's Pharma Package and Specialty Drug Tariff Exemptions
4
Your Patient Support Data Shows What Happened. Can It Tell You Why?
5